{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:28:03Z","timestamp":1782602883327,"version":"3.54.5"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.7966-16","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T22:17:04Z","timestamp":1512080224000},"page":"3237-3241","source":"Crossref","is-referenced-by-count":7,"title":["Hemophagocytic Syndrome Complicated with Dermatomyositis Controlled Successfully with Infliximab and Conventional Therapies"],"prefix":"10.2169","volume":"56","author":[{"given":"Yoji","family":"Komiya","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Mizoguchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kohsaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Janka GE, Lehmberg K. Hemophagocytic syndromes - an update. Blood Rev 28: 135-142, 2014.","DOI":"10.1016\/j.blre.2014.03.002"},{"key":"2","unstructured":"2. Henter JI, Horne A, Aric\u00f3 M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48: 124-131, 2007."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndromes in adults. Arthritis Rheum 66: 2297-2307, 2014.","DOI":"10.1002\/art.38672"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takeoka Y, Nakamae M, Nakamae H, et al. Two cases of ampulla (takotsubo-shaped) cardiomyopathy associated with hemophagocytic lymphohistiocytosis. Acta Haematol 117: 205-210, 2007.","DOI":"10.1159\/000098461"},{"key":"5","unstructured":"5. Thomas A, Appiah J, Langsam J, Parker S, Christian C. Hemophagocytic lymphohistiocytosis associated with dermatomyositis: a case report. Conn Med 77: 481-485, 2013."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kaieda S, Yoshida N, Yamashita F, et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. Mod Rheumatol 25: 962-966, 2015.","DOI":"10.3109\/14397595.2013.844402"},{"key":"7","unstructured":"7. Yajima N, Wakabayashi K, Odai T, et al. Clinical features of hemophagocytic syndrome in patients with dermatomyositis. J Rheumatol 35: 1838-1841, 2008."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mizoguchi F, Takada K, Ishikawa K, Mizusawa H, Kohsaka H, Miyasaka N. A case of dermatomyositis with rhabdomyolysis, rescued by intravenous immunoglobulin. Mod Rheumatol 25: 646-648, 2015.","DOI":"10.3109\/14397595.2013.843753"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Madaule S, Porte L, Couret B, Arlet-Suau E. Fatal haemophagocytic syndrome in the course of dermatomyositis with anti-Mi2 antibodies. Rheumatology (Oxford) 39: 1157-1158, 2000.","DOI":"10.1093\/rheumatology\/39.10.1157"},{"key":"10","unstructured":"10. Bazan-Socha S, Zolcinski M, Szostek M, et al. A fatal case of acquired hemophagocytic lymphohistiocytosis (macrophage activation syndrome) in the initial course of dermatomyositis with anti-Jo-1 antibody. Int J Rheum Dis in press."},{"key":"11","unstructured":"11. Yamashita H, Matsuki Y, Shimizu A, et al. Hemophagocytic lymphohistiocytosis complicated by central nervous system lesions in a patient with dermatomyositis: a case presentation and literature review. Mod Rheumatol 23: 386-392, 2013."},{"key":"12","unstructured":"12. Poddighe D, Cavagna L, Brazzelli V, Bruni P, Marseglia GL. A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria. Autoimmun Rev 13: 1142-1148, 2014."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ideguchi H, Ohno S, Takase K, et al. Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheumatology (Oxford) 46: 1621-1622, 2007.","DOI":"10.1093\/rheumatology\/kem205"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndromes in adults. Arthritis Rheum 66: 2297-2307, 2014.","DOI":"10.1002\/art.38672"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 81: 59-61, 2006.","DOI":"10.1002\/ajh.20462"},{"key":"16","unstructured":"16. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65: 1233-1236, 2006."},{"key":"17","unstructured":"17. Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 26: 1186-1188, 2007."},{"key":"18","unstructured":"18. Coyle K, Pokrovnichka A, French K, et al. A Randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Res 58: s293, 2008."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67: 1670-1677, 2008.","DOI":"10.1136\/ard.2007.077974"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Callen JP. Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep 12: 192-197, 2010.","DOI":"10.1007\/s11926-010-0100-7"},{"key":"21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000368552","volume":"230","author":"ML Zerah","year":"2015","unstructured":"21. Zerah ML, DeWitt CA. Cutaneous findings in hemophagocytic lymphohistiocytosis. Dermatology 230: 234-243, 2015.","journal-title":"Dermatology","ISSN":"https:\/\/id.crossref.org\/issn\/1018-8665","issn-type":"print"},{"key":"22","unstructured":"22. Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Pract Res Clin Rheumatol 18: 429-462, 2004."},{"key":"23","unstructured":"23. Carter JD, Kanik KS, Vasey FB, Valeriano-Marcet J. Dermatomyositis with normal creatine kinase and elevated aldolase levels. J Rheumatol 28: 2366-2367, 2001."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Gunst JJ, Langlois MR, Delanghe JR, De Buyzere ML, Leroux-Roels GG. Serum creatine kinase activity is not a reliable marker for muscle damage in conditions associated with low extracellular glutathione concentration. Clin Chem 44: 939-943, 1998.","DOI":"10.1093\/clinchem\/44.5.939"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kwon WY, Suh GJ, et al. Plasma glutathione reductase activity and prognosis of septic shock. J Surg Res 200: 298-307, 2016.","DOI":"10.1016\/j.jss.2015.07.044"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bavunoglu I, Genc H, Konukoglu D, et al. Oxidative stress parameters and inflammatory and immune mediators as markers of the severity of sepsis. J Infect Dev Ctries 10: 1045-1052, 2016.","DOI":"10.3855\/jidc.7585"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Pajtler KW, Tippelt S, Siegler N, et al. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. J Neurooncol 128: 463-471, 2016.","DOI":"10.1007\/s11060-016-2133-x"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Patel RA, Gallagher JC. Drug fever. Pharmacotherapy 30: 57-69, 2010.","DOI":"10.1592\/phco.30.1.57"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/23\/56_7966-16\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T09:12:13Z","timestamp":1603444333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/23\/56_7966-16\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":28,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7966-16","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}